Stockscreener 앱 받기
0.7498
4.90%
-0.0386
Propanc Biopharma Inc 주식(PPCB)의 최신 뉴스
Propanc Biopharma, Inc. (PPCB) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Propanc Biopharma Shares Gain After Seeking Patent Protection for New Cancer and Fibrosis Treatments - MSN
Propanc Biopharma Inc. (PPCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Propanc Biopharma, Inc. (PPCB) -6.3% in After-hours: Shares Slide Amid Investigation Announcement - Stocks Telegraph
Propanc Biopharma Investigates 'Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) targets fibrosis, cancer via PRP EMT research - Stock Titan
Views of Wall Street’s Leading Experts on Propanc Biopharma Inc - setenews.com
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga
Propanc Biopharma files patents for resistant cancer and fibrosis treatments By Investing.com - Investing.com Australia
Propanc Biopharma stock rises after filing for patents to treat resistant cancer By Investing.com - Investing.com South Africa
Propanc Biopharma stock rises after filing for patents to treat resistant cancer - Investing.com Australia
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - The Manila Times
Propanc Biopharma files patents for resistant cancer and fibrosis treatments - Investing.com
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant ... - Enidnews.com
Propanc Biopharma (Nasdaq: PPCB) moves to patent PRP use in fibrosis ahead of 2026 Phase 1b trial - Stock Titan
Propanc Biopharma secures up to $100 million private placement - MSN
Propanc Biopharma Inc Share PricePPCB, RNS News, Articles, Quotes, & Charts (OTCMKTS:PPCB) - Proactive financial news
Australian firm launches crypto treasury for the future of cancer drug - Proactive financial news
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) Raises $4M, Lists on Nasdaq, Sets $100M Facility - Stock Titan
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Propanc Biopharma Secures $1M Through Stock Sale - MSN
Propanc Biopharma Secures $100M Crypto Deal for Cancer Breakthrough - Analytics Insight
Propanc Biopharma Secures Up to $100M to Build Crypto Treasury and Advance Cancer Therapy Trials - Bitget
The time has not yet come to remove your chips from the table: Propanc Biopharma Inc (PPCB) - setenews.com
Propanc Biopharma (PPCB) Stock: Crypto Treasury Plan Triggers Massive Sell-Off - parameter.io
Propanc Biopharma (PPCB) Stock: Biotech Secures $100M Crypto Funding as Shares Tumble - Blockonomi
Propanc, The Australian Biotech, Turns To Crypto To Tackle Cancer - Bitcoinist.com
Propanc Biopharma (PPCB) Stock: Company Secures $100M Crypto Treasury Deal - CoinCentral
Propanc Biopharma secures up to $100 million investment from Hexstone By Investing.com - Investing.com Nigeria
Propanc Biopharma secures $1 million initial investment from Hexstone By Investing.com - Investing.com Nigeria
Propanc Biopharma Secures $100M to Build Crypto Treasury - Coinpaper
Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5% - Bitget
Biopharma raises $100M for crypto treasury to back cancer treatment - TradingView
[8-K] Propanc Biopharma, Inc. Reports Material Event | PPCB SEC FilingForm 8-K - Stock Titan
Biotech firm Propanc lines up $100 million to fund crypto treasury and cancer therapy push - TradingView
Propanc Biopharma, Inc. announced that it has received $1 million in funding from Hexstone Capital, LLC - MarketScreener
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) secures up to $100M to fund digital assets; $1M received - Stock Titan
Taking on analysts’ expectations and winning: Propanc Biopharma Inc (PPCB) - setenews.com
Propanc Biopharma plans digital asset company acquisitions By Investing.com - Investing.com Nigeria
Propanc Biopharma plans digital asset company acquisitions - Investing.com India
0.36%
1.05%
자본화:
|
볼륨(24시간):